Clinical Trials Logo

Irritable Bowel Syndrome clinical trials

View clinical trials related to Irritable Bowel Syndrome.

Filter by:

NCT ID: NCT05631860 Completed - Fibromyalgia Clinical Trials

Psychological Risk Factors for Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The objective of this study is to explore the role of neuroticism, perceived stress, and adverse life events, respectively, in the development and perpetuation of functional somatic disorders.

NCT ID: NCT05619341 Completed - Irritable Bowel Clinical Trials

Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON)

EON
Start date: October 28, 2022
Phase: N/A
Study type: Interventional

To test whether slowing the rate of delivery of inulin with either psyllium or divided dosing of inulin, will reduce colonic gas production as compared to inulin combined with placebo. To obtain pilot data on link between habitual diet and fermentation of inulin.

NCT ID: NCT05618106 Completed - Clinical trials for Irritable Bowel Syndrome

Low FODMAP Diet in Patients With IBS

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The aim was aimed to investigate if all carbohydrate groups eliminated in the Low FODMAP diet are equally important in relieving gastrointestinal symptoms in IBS. in a randomized cross-over design to three different carbohydrate-modified diets: A) Low Polyol diet, B) Low FOS+GOS diet, and C) Low FODMAP diet for three months without wash-out-periods. Gastrointestinal symptoms, Quality of life was measured at baseline and after each intervention diet.

NCT ID: NCT05616429 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Alcat Based Elimination Diet for the Treatment of Irritable Bowel Syndrome; a Randomized Double Blind Sham Control Trial

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Irritable bowel syndrome (IBS) is the most common GI condition with global prevalence ranging between 10-20%. Although the exact cause is not known there are increasing insights concerning the possible multifactorial etiology including low grade inflammation, neuromodulation, dysbiosis, impaired integrity of the intestinal barrier and more. Currently, it is believed that changes in the microbiota may activate mucosal innate immune responses, resulting in increased epithelial permeability, activated nociceptive sensory pathways, and dysregulation of the enteric nervous system. Nearly two thirds of patients with IBS perceive their GI symptoms to be food related, hence, food intolerance may be important factor in the pathogenesis. Diet is a part of IBS treatment but adherence, on the one hand, and restriction, on the other, remain a major problem. [Chey WD, Am J Gastroenterol,2016]. Confocal laser endomicroscopy (CLE) is a technique that permits real-time detection and quantification of changes in intestinal tissues and cells, including increases in intraepithelial lymphocytes and fluid extravasation through epithelial leaks. Based on CLE analysis of IBS patients with a suspected food intolerance, exposure to candidate food antigens caused immediate breaks, increased intervillous spaces, and increased IELs in the intestinal mucosa. These changes are associated with patient responses to exclusion diets. [Fritscher-Ravens A et al, Gastroenterology. 2019, Gastroenterology. 2014] This technic, also efficient according to former studies, is costly and invasive. The Alcat Test is a lab based immune stimulation test in which a patient's WBC's (white blood cell) are challenged with various substances including foods, additives, colorings, chemicals, medicinal herbs, functional foods, molds and pharmaceutical compounds. The Alcat Test objectively classifies a patient's response to each test substance as reactive, borderline or non-reactive. Based on these classifications, a customized elimination/rotation diet may be designed.

NCT ID: NCT05611606 Completed - Fibromyalgia Clinical Trials

Welfare Benefits in Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The objective of this observational study is to estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with functional somatic disorders and compare them to 1. healthy individuals, and 2. individuals with severe physical disease.

NCT ID: NCT05573685 Completed - Clinical trials for Rheumatoid Arthritis

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Start date: October 10, 2022
Phase: N/A
Study type: Interventional

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).

NCT ID: NCT05565612 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome

Start date: October 10, 2022
Phase: N/A
Study type: Interventional

The clinical trial has a randomized, double-blind and placebo-controlled design, in which the effect of a probiotic mix wants to be evaluated, with a treatment of 12 weeks, in the evolution of the symptoms of Irritable Bowel Syndrome. The 12 weeks of the treatment are structured in four in-person visits: Visit 1 (initial; week 0), Visit 2 (halfway; week 4), Visit 3 (halfway; week 8) and Visit 4 (final; week 12).

NCT ID: NCT05523427 Completed - Clinical trials for Irritable Bowel Syndrome

Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome

Start date: July 19, 2022
Phase: N/A
Study type: Interventional

Studying the effects of adding probiotics to the drug regimen of patients with diarrhea predominant IBS

NCT ID: NCT05475314 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Effect of Postbiotic Product on Colonic Barriers in IBS

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this experimental study, we investigated whether ReFerm® has a beneficial effect on the intestinal epithelial barrier function in patients with IBS.

NCT ID: NCT05461833 Completed - Clinical trials for Irritable Bowel Syndrome

FMT for Post-infectious IBS

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Considering that PI-IBS is brought on by infection and gut microbiota may be associated with the onset of symptoms, the modification of altered gut microbiota with nonabsorbable antibiotics such as rifaximin-α or probiotics is often employed as first-stage treatment. Research in recent years has also shown the potential benefits of fecal microbiota transplantation (FMT) for IBS, which is the replacement of a sick recipient's gut microbiota with fecal material from a healthy donor. Even though the only officially approved indication for FMT at this time is recurrent Clostridium difficile infection, the effectiveness of FMT is nevertheless being studied for the treatment of other gastrointestinal and non-gastrointestinal pathologies including IBS. To date, several controlled and uncontrolled studies have been conducted to study the effectiveness of FMT for IBS, and most of them have demonstrated positive results. The investigators have not come across studies devoted to the study of the effectiveness of FMT in patients with PI-IBS in the available literature. So, the aim of the current study was to conduct single-centre, randomized clinical trial to assess the safety, clinical and microbiological efficacy of FMT in patients with PI-IBS.